We are pleased to see further progress in the Pennsylvania litigation involving Risperdal lawsuits, as we have already filed several Risperdal gynecomastia claims in the Philadelphia Court of Common Pleas.
New York, NY (PRWEB) June 15, 2014
A consolidated litigation involving Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) is continuing to move forward in Pennsylvania state court, where an upcoming status conference is scheduled to take place next month, Bernstein Liebhard LLP reports.
According to a calendar posted on the Court’s website, parties in the litigation will convene at a conference held in the Philadelphia Court of Common Pleas on July 15, 2014 at 11:00 a.m. There, parties will likely discuss matters related to Risperdal lawsuits, which similarly accuse Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, of failing to adequately warn about side effects allegedly associated with the atypical antipsychotic medication. Many of the cases filed in this proceeding allege symptoms associated with Risperdal gynecomastia, a condition categorized by male breast growth. (Risperdal Litigation, case number 100300296)
“We are pleased to see further progress in the Pennsylvania litigation involving Risperdal lawsuits, as we have already filed several Risperdal gynecomastia claims in the Philadelphia Court of Common Pleas,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is currently offering free and confidential case evaluations to men and young boys who allege injuries caused by Risperdal.
According to court documents, more than 500 Risperdal lawsuits alleging gynecomastia and other side effects have now been filed in the Pennsylvania state court litigation. Plaintiffs in these cases claim that use of the atypical antipsychotic can cause the body to produce excessive amounts of prolactin, a hormone associated with breast growth in young girls and milk production in women. According to Risperdal lawsuits, the hormone can have similar effects on male patients, leading to liposuction and mastectomy procedures to remove the excess breast tissue that allegedly developed because of the medication.
Risperdal is an atypical antipsychotic approved by the U.S. Food and Drug Administration (FDA) to treat bipolar disorder and schizophrenia in adults and adolescents between the ages of 10 and 17, as well as irritability in children aged between 5 and 16 with autistic disorder. According to research, Risperdal may also be frequently prescribed off-label for symptoms associated with ADHD.*
In addition to hundreds of product liability lawsuits that accuse Johnson & Johnson and Janssen of promoting Risperdal for uses not approved by the FDA, the U.S. Department of Justice filed claims against the companies that ultimately resulted in a $2.2 billion settlement from the medical device manufacturer in November 2013. To resolve claims that Risperdal was marketed to elderly patients with dementia and for pediatric uses before it was approved to do so in 2006, Johnson & Johnson agreed to pay $2.2 billion to the federal government. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and young boys who allegedly developed male breasts after taking Risperdal may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn more about how a Risperdal lawyer can help you by visiting Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.
*health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com